View of Heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) as a pathogenetically significant drug target for oncology therapy (molecular docking of irinotecan and doxycycline)

Return to Article Details Heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) as a pathogenetically significant drug target for oncology therapy (molecular docking of irinotecan and doxycycline) Download Download PDF